Yahoo Finance

WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19

Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification.
Yahoo Finance

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

The authorisation enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalised adult and paediatric patients Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
FiercePharma

Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy

Statistically significant greater improvement in signs and symptoms, as measured by mean change in DAS28 (primary endpoint), DAS28 remission and low disease activity, ACR20, 50 and 70 (secondary ...
PharmiWeb

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

Basel, 07 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the ...
PMLiVE

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (tocilizumab). The drug contains the active ingredient tocilizumab and has been ...
PharmaTimes

Final NHS nod for Roche’s RoActemra

Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
FiercePharma

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis First anti IL-6 receptor ...
FierceBiotech

Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with ...
Nasdaq

Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis ...

Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...
PharmaTimes

NHS use of Roche’s Roactemra turned down for giant cell arteritis

It is looking unlikely that patients with giant cell arteritis will get NHS access to Roche’s Roactemra, after the drug was turned down by cost regulators in draft guidelines. It is looking unlikely ...
BioWorld

Items Tagged with 'Roactemra'

LONDON – The U.K. Recovery trial has added a fourth drug to the list of therapies it has shown are effective in treating hospitalized COVID-19 patients, demonstrating the JAK inhibitor Olumiant ...